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Background: There are 3 classes of HLA molecules; HLA class I, II and III, of which
different classes have different functions. HLA-B gene which belongs to HLA class I play
an important role predicting drug hypersensitivity.
Materials and Methods: Nine hundred and eighty-six Thai subjects who registered at a
pharmacogenomics laboratory were determined for HLA-B genotype using a two-stage
sequence-specific oligonucleotide probe system (PCR-SSOP).
Results: In this study, HLA-B alleles did not deviate from Hardy-Weinberg equilibrium (P >
0.05). The most common HLA-B alleles observed in this population were HLA-B∗46:01
(11.51%), HLA-B∗58:01 (8.62%), HLA-B∗40:01 (8.22%), HLA-B∗15:02 (8.16%) and
HLA-B∗13:01 (6.95%). This finding revealed that HLA-B allele frequency in the Thai
population was consistent with the Chinese population (p > 0.05), however, differed
from the Malaysian population (p < 0.05). The top five HLA-B genotypes were
HLA-B∗40:01/46:01 (2.13%), HLA-B∗46:01/46:01 (2.03%), HLA-B∗40:01/58:01 (2.03%),
HLA-B∗46:01/58:01 (1.93%) and HLA-B∗15:02/46:01 (1.83%). This study found that
15.92% of Thai subjects carry HLA-B∗15:02, which has been associated with
carbamazepine-induced severe cutaneous adverse drug reactions (SCARs). Moreover,
16.33% of Thai subjects carry the HLA-B∗58:01 allele, which has been associated with
allopurinol-induced SCARs.
Conclusion: This study demonstrates a high diversity of HLA-B polymorphisms in this
Thai population. The high frequency of HLA-B pharmacogenomic markers in the population
emphasizes the importance of such screening to predict/avoid drug hypersensitivity.
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INTRODUCTION
Human leukocyte antigen (HLA) genes are located in the short
arm of chromosome 6, are part of a large family of genes,
and are inherited from both parents, one of paternal origin
and one of maternal origin for each of the loci (Alper et al.,
2006). HLA proteins are present at the cellular surface of antigen
presenting cells. There are 3 classes of HLA. Class I loci (HLA-
A, -B, -C) present endogenous antigens such as viral protein
or tumor antigen to CD8+ T cells. Class II loci (HLA-DR, -
DQ, -DP) present exogenous antigens to CD4+ T cells. Class
III (Bf, C2, C4A) are involved in the complement system. HLA
genes are highly polymorphic, which becomes important in asso-
ciations of susceptibility or resistance to disease, development
of tumor processes, molecular vaccine development (Dawson
et al., 2001) and determination of organ or tissue transplant sur-
vival (Dhaliwal et al., 2003; Avila-Rios et al., 2009). In addition,
HLA allele frequency might be useful in anthropological studies.
Previous studies have reported HLA allele and haplotype fre-
quencies of Thai populations. The most common HLA haplo-
types were A∗33-Cw∗0302-B∗5801-DRB∗0301-DQB1∗02 (4.6%),
A∗0207-Cw∗01-B∗4601-DRB1∗09-DQB1∗0303 (3.4%) and A∗33-
Cw∗07 (01-03)-B∗44-DRB1∗07-DQB1∗02 (2.6%) (Kupatawintu
et al., 2010; Romphruk et al., 2010).
HLA-B alleles have been used as a marker for predicting drug-
induced adverse reactions (Sukasem et al., 2014a) and are a
major contributor to hypersensitivity reactions involving direct
stimulation of immune effector cells and imitating an aller-
gic reaction. Several studies reported that allopurinol-induced
severe cutaneous adverse reactions (SCARs) are strongly asso-
ciated with the HLA-B∗58:01 allele in Han Chinese and Thais
(Hung et al., 2005; Tassaneeyakul et al., 2009; Jantararoungtong
et al., 2014). The HLA-B∗15:02 allele was strongly related to
carbamazepine-induced Steven-Johnson syndrome (SJS)-toxic
epidermal necrolysis (TEN) in Taiwanese and Thai populations
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(Tassaneeyakul et al., 2010; Chen et al., 2011; Sukasem et al.,
2014b). Importantly, Thais showed cutaneous adverse reac-
tions associated with HLA-B∗35:05 (Chantarangsu et al., 2009,
2011). In addition, the HLA-B∗57:01 allele is involved in
abacavir-induced hypersensitivity reaction (Mallal et al., 2008).
Consequently, screening of HLA-B genotyping before prescrip-
tion of medication may reduce the risk of SCARs and drug
hypersensitivity reaction.
Presently, HLA-B genotyping is available in clinical practices
before commencing therapy with the aforementioned drugs in
Thailand (Sukasem et al., 2014a). This study aimed to determine
the distribution of HLA-B haplotypes, and to establish the most
common HLA haplotype-associated drug induced hypersensitiv-
ity using routine pharmacogenomic laboratory procedures. Over
a period of 3 years, HLA-B allele genotype was analyzed in 986
Thai people registered at the Laboratory for Pharmacogenomics,
Ramathibodi Hospital, Thailand. The frequency of HLA-B alle-
les andHLA-B genotypes were determined and used to define the
probability associated with a Pharmacogenomic marker indicat-
ing adverse drug reaction.
MATERIALS AND METHODS
SUBJECTS AND CHARACTERISTICS
A descriptive, observational, cross-sectional, retrospective study
was conducted in 986 unrelated individuals. Data were col-
lected at the Laboratory for Pharmacogenomics, Somdech Phra
Debaratana Medical Center (SDMC), Ramathibodi Hospital,
Bangkok, Thailand during August 2011–June 2014. Among these
patients, there were 590 (59.83%) males and 396 (40.17%)
females. Themean age of patients at recruitment was 41.98± 4.40
years. The study was approved by the Ethics Committee of the
Faculty of Medicine, Ramathibodi Hospital, Mahidol University.
The protocol number is ID 04-56-24.
GENOMIC DNA EXTRACTION
Blood samples were collected into EDTA tubes. DNA was isolated
using theMagNA Pure automated extraction system (Roche diag-
nostics, USA), which uses magnetic-bead technology with a lysis
buffer and proteinase K. Nucleic acids bind to the surface of the
magnetic glass particles. Cellular debris was removed by several
washing steps and the purified nucleic acids were eluted. From the
1ml input volume of EDTA-whole blood, 200µL output volume
of extracted genomic DNA product was obtained.
The quality of genomic DNAwas assessed by using Nano Drop
ND-1000. Genomic DNA was detected by measuring absorbance
at 260 nm. Purity of the sample was evaluated by calculation of
the optical density (OD) ratio, 260/280 nm. The recommended
purified genomic DNA template for this study was 20 ng, and the
OD ratio greater than 1.7. All DNA was aliquotted and stored
at −20◦C before analysis.
HLA-B TYPING
HLA-B genotyping was carried out using the Luminex™
Multiplex Technology (Luminex®IS 100, USA) based on
Polymerase Chain Reaction-sequence specific oligonucleotides
probe (PCR-SSOP) principles. Briefly, the PCR products were
hybridized against a panel of oligonucleotide probes coated onto
polystyrene microspheres. Probe sequences were complementary
to stretches of polymorphic sequence within the target HLA-
B alleles. The amplicon-probe complex was visualized using
a colorimetric reaction and fluorescence detection technology.
Data analyses for the HLA-B assays were performed with HLA
fusion™2.0 software.
STATISTICAL ANALYSIS
The HLA-B allele frequencies of the samples were assayed by
direct counting and, subsequently, by dividing the total num-
ber of occurrences of that allele by the total number of alleles
at that locus in the population. The samples were also evaluated
for Hardy-Weinberg equilibrium using the Chi-square or Fisher’s
exact test if the number in any cell of the 2 × 2 contingency tables
was less than five.
RESULTS
HLA-B ALLELE FREQUENCY
The study population comprised 986 samples which were
obtained from Laboratory for Pharmacogenomics, Somdech Phra
Debaratana Medical Center (SDMC), Ramathibodi Hospital,
Thailand. The frequency of HLA-B alleles in 986 Thai patients
is shown in Table 1. Overall, 116 different HLA-B alleles were
identified in this study, and HLA-B∗46:01 (11.51%) was the
predominant allele in this population. The most frequent alle-
les were HLA-B∗46:01 (11.51%), HLA-B∗58:01 (8.62%), HLA-
B∗40:01 (8.22%), HLA-B∗15:02 (8.16%), HLA-B∗13:01 (6.95%)
and HLA-B∗44:03 (4.21%). The frequencies of HLA-B alleles do
not significantly deviate from Hardy-Weinberg equilibrium.
FREQUENCY OF HLA-B GENOTYPE OCCURRENCE
Overall, there were 448 different HLA-B genotypes in the
986 Thai individuals analyzed. The most frequently observed
Table 1 | Identified HLA-B allelic frequencies in Thai population
(n = 986).
Alleles No. of AF Estimated No. of Genotype HW
alleles (%) genotype genotypes frequency (%) p-value
B*07:02 15 0.76 0.06 0 0.00 1
B*07:05 38 1.93 0.37 0 0.00 1
B*07:13 1 0.05 0.00 0 0.00 1
B*07:14 1 0.05 0.00 0 0.00 1
B*08:01 13 0.66 0.04 0 0.00 1
B*08:02 1 0.05 0.00 0 0.00 1
B*08:03 1 0.05 0.00 0 0.00 1
B*08:12 1 0.05 0.00 0 0.00 1
B*13:01 137 6.95 4.76 6 0.61 1
B*13:02 27 1.37 0.18 0 0.00 1
B*13:03 1 0.05 0.00 0 0.00 1
B*13:39 3 0.15 0.00 0 0.00 1
B*14:13 1 0.05 0.00 0 0.00 1
B*15:01 27 1.37 0.18 1 0.10 1
B*15:02 161 8.16 6.57 8 0.81 1
B*15:04 4 0.20 0.00 0 0.00 1
(Continued)
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Table 1 | Continued
Alleles No. of AF Estimated No. of Genotype HW
alleles (%) genotype genotypes frequency (%) p-value
B*15:06 1 0.05 0.00 0 0.00 1
B*15:07 3 0.15 0.00 0 0.00 1
B*15:11 5 0.25 0.01 0 0.00 1
B*15:12 12 0.61 0.04 0 0.00 1
B*15:13 11 0.56 0.03 0 0.00 1
B*15:17 4 0.20 0.00 0 0.00 1
B*15:18 3 0.15 0.00 0 0.00 1
B*15:20 2 0.10 0.00 0 0.00 1
B*15:21 3 0.15 0.00 0 0.00 1
B*15:22 1 0.05 0.00 0 0.00 1
B*15:25 28 1.42 0.20 0 0.00 1
B*15:27 2 0.10 0.00 0 0.00 1
B*15:31 4 0.20 0.00 0 0.00 1
B* 15:32 7 0.35 0.01 0 0.00 1
B*15:35 17 0.86 0.07 1 0.10 1
B*15:88 1 0.05 0.00 0 0.00 1
B*18:01 63 3.19 1.01 0 0.00 1
B*18:01 1 0.05 0.00 0 0.00 1
B*18:02 45 2.28 0.51 0 0.00 1
B*18:02 1 0.05 0.00 0 0.00 1
B*18:09 1 0.05 0.00 0 0.00 1
B*18:18 1 0.05 0.00 0 0.00 1
B*27:03 3 0.15 0.00 0 0.00 1
B*27:04 32 1.62 0.26 0 0.00 1
B*27:06 18 0.91 0.08 0 0.00 1
B*27:61 10 0.51 0.03 0 0.00 1
B*27:86 1 0.05 0.00 0 0.00 1
B*35:01 29 1.47 0.21 0 0.00 1
B*35:02 2 0.10 0.00 0 0.00 1
B*35:03 17 0.86 0.07 0 0.00 1
B*35:05 40 2.03 0.41 1 0.10 1
B*35:08 1 0.05 0.00 0 0.00 1
B*35:11 1 0.05 0.00 0 0.00 1
B*35:13 1 0.05 0.00 0 0.00 1
B*35:20 1 0.05 0.00 0 0.00 1
B*35:23 1 0.05 0.00 0 0.00 1
B*35:58 1 0.05 0.00 0 0.00 1
B*35:68 2 0.10 0.00 0 0.00 1
B*37:01 8 0.41 0.02 0 0.00 1
B*38:01 2 0.10 0.00 0 0.00 1
B*38:02 61 3.09 0.94 3 0.30 0.624
B*38:17 1 0.05 0.00 0 0.00 1
B*38:22 1 0.05 0.00 0 0.00 1
B*38:23 2 0.10 0.00 0 0.00 1
B*39:01 14 0.71 0.05 0 0.00 1
B*39:09 18 0.91 0.08 0 0.00 1
B*39:15 13 0.66 0.04 0 0.00 1
B*39:24 5 0.25 0.01 0 0.00 1
B*40:01 162 8.22 6.65 6 0.61 1
B*40:02 30 1.52 0.23 0 0.00 1
B*40:03 1 0.05 0.00 0 0.00 1
(Continued)
Table 1 | Continued
Alleles No. of AF Estimated No. of Genotype HW
alleles (%) genotype genotypes frequency (%) p-value
B*40:04 7 0.35 0.01 0 0.00 1
B*40:06 14 0.71 0.05 1 0.10 1
B*40:09 1 0.05 0.00 0 0.00 1
B*40:10 6 0.30 0.01 0 0.00 1
B*40:23 1 0.05 0.00 0 0.00 1
B*40:59 1 0.05 0.00 0 0.00 1
B*41:01 1 0.05 0.00 0 0.00 1
B*41:10 1 0.05 0.00 0 0.00 1
B*44:01 2 0.10 0.00 0 0.00 1
B*44:02 14 0.71 0.05 0 0.00 1
B*44:02 1 0.05 0.00 0 0.00 1
B*44:03 83 4.21 1.75 1 0.10 1
B*44:54 1 0.05 0.00 0 0.00 1
B*46:01 227 11.51 13.07 20 2.03 0.292
B*46:12 26 1.32 0.17 1 0.10 1
B*46:16 1 0.05 0.00 0 0.00 1
B*48:01 9 0.46 0.02 0 0.00 1
B*48:03 7 0.35 0.01 0 0.00 1
B*48:21 1 0.05 0.00 0 0.00 1
B*50:01 11 0.56 0.03 0 0.00 1
B*51:01 65 3.30 1.07 0 0.00 1
B*51:02 16 0.81 0.06 0 0.00 1
B*51:04 4 0.20 0.00 0 0.00 1
B*51:06 3 0.15 0.00 0 0.00 1
B*51:07 1 0.05 0.00 0 0.00 1
B*51:43 1 0.05 0.00 0 0.00 1
B*51:45 1 0.05 0.00 0 0.00 1
B*52:01 43 2.18 0.47 0 0.00 1
B*52:07 1 0.05 0.00 0 0.00 1
B*53:17 5 0.25 0.01 0 0.00 1
B*54:01 21 1.06 0.11 0 0.00 1
B*54:01 2 0.10 0.00 0 0.00 1
B*54:04 1 0.05 0.00 0 0.00 1
B*54:16 1 0.05 0.00 0 0.00 1
B*55:01 8 0.41 0.02 0 0.00 1
B*55:02 23 1.17 0.13 0 0.00 1
B*55:03 1 0.05 0.00 0 0.00 1
B*55:04 2 0.10 0.00 0 0.00 1
B*55:10 1 0.05 0.00 0 0.00 1
B*55:44 2 0.10 0.00 0 0.00 1
B*56:01 15 0.76 0.06 0 0.00 1
B*56:01 1 0.05 0.00 0 0.00 1
B*56:02 1 0.05 0.00 0 0.00 1
B*56:04 6 0.30 0.01 0 0.00 1
B*56:16 3 0.15 0.00 0 0.00 1
B*57:01 30 1.52 0.23 0 0.00 1
B*57:21 2 0.10 0.00 0 0.00 1
B*58:01 170 8.62 7.33 9 0.91 1
B*58:34 1 0.05 0.00 0 0.00 1
Total 1972 100
AF, Allele frequencies; H-W, Hardy-Weinberg equilibrium.
www.frontiersin.org January 2015 | Volume 5 | Article 478 | 3
Puangpetch et al. HLA-B genotype and pharmacogenomic markers
Table 2 | Top 10 common genotypes in the Thais (n = 986).
Genotypes No. of subjects Frequency (%)
B*40:01/46:01 21 2.13
B*46:01/46:01 20 2.03
B*40:01/58:01 20 2.03
B*46:01/58:01 19 1.93
B*15:02/46:01 18 1.83
B*15:02/40:01 15 1.52
B*13:01/58:01 13 1.32
B*13:01/15:02 12 1.22
B*13:01/46:01 11 1.12
B*38:02/46:01 11 1.12
B*15:02/44:03 11 1.12
B*13:01/40:01 10 1.01
HLA-B genotype was HLA-B∗40:01/46:01. The 10 most com-
mon genotype frequencies in this Thai population were
HLA-B∗40:01/46:01 (2.13%), HLA-B∗46:01/46:01 (2.03%), HLA-
B∗40:01/58:01 (2.03%), HLA-B∗46:01/58:01 (1.93%), HLA-B∗
15:02/46:01 (1.83%), HLA-B∗15:02/40:01 (1.52%), HLA-B∗
13:01/58:01 (1.32%), HLA-B∗13:01/15:02 (1.22%), HLA-B∗
13:01/46:01 (1.12%), HLA-B∗38:02/46:01 (1.12%), HLA-B∗
15:02/44:03 (1.12%), and HLA-B∗13:01/40:01 (1.01%). None of
these genotypes were present in more than 5% of the population.
Table 2 shows the frequency of the top 10 genotypes the Thai
population in this study.
FREQUENCY OF THE STRONG PREDICTION OF HLA-B
PHARMACOGENOMICS MARKERS IN THAI POPULATION
With regard to HLA-B pharmacogenomic markers in the Thai
population, high frequencies of HLA-B∗ 58:01 (16.33%) were
observed, followed by HLA-B∗15:02 (15.92%), HLA-B∗ 35:05
(4.36%), and HLA-B∗57:01 (3.04%). Table 3 shows the frequen-
cies of the genotypes of HLA-B pharmacogenomic markers in
this Thai population. Of the 986 subjects who were included
in the study, 161 subjects (16.43%) were found to carry the
HLA-B∗58:01 allele. One hundred and fifty-two subjects carry
the heterozygous HLA-B∗58:01 genotype and 9 subjects carry the
homozygous HLA-B∗58:01 genotype. Among these, 56.02% were
males and 43.98% were female.
HLA-B∗15:02 is a genetic marker previously related to induc-
tion of SJS/TEN in carbamazepine treated patients. One hun-
dred and fifty-seven subjects (15.92%) were found to carry
HLA-B*15:02; 151 subjects (15.31%) were heterozygous for the
HLA-B∗15:02 allele and 8 subjects (0.81%) carry homozygous
HLA-B∗15:02. Males accounted for 60.23% and females 39.77%.
In addition, HLA-B∗15:02 belong to the HLA-B75 family, which
consists of HLA-B∗15:08, HLA-B∗15:11, HLA-B∗15:18 and HLA-
B∗15:21, and is associated with carbamazepine-induced SJS/TEN.
Five subjects with HLA-B∗15:11 heterozygous genotype and 3
subjects with HLA-B∗15:18, HLA-B∗15:21 heterozygous geno-
type were found, whereas HLA-B∗15:08 was not found in either
heterozygous and homozygous genotypes in this population.
Likewise, the HLA-B∗3505 allele was associated with
nevirapine-induced hypersensitivity reactions in HIV-infected
Thai patients. Forty-three subjects (4.36%) carried the
HLA-B∗35:05 allele, one subject and 42 subjects (4.26%)
carry homozygous and heterozygous HLA-B∗35:05 genotypes,
respectively, Thirty subjects (3.04%) carry heterozygous HLA-
B∗57:01, which is known to be associated with abacavir-induced
hypersensitivity syndrome (AHS). No homozygousHLA-B∗57:01
genotype was identified in this study.
DISCUSSION
The HLA-B allele frequencies of 968 Thai subjects were inves-
tigated. This is the first report of HLA-B genotyping in the
Thai population using the Luminex HLA-SSOP method. Our
data showed that the Thai population has extensive diver-
sity at the HLA-B locus. One hundred and sixteen allele
types were identified and the frequencies of HLA-B alleles
did not significantly deviate from Hardy-Weinberg equilibrium.
The top five alleles with frequencies over 5% include HLA-
B∗46:01 (11.51%),HLA-B∗58:01 (8.62%),HLA-B∗40:01 (8.22%),
HLA-B∗15:02 (8.16%), and HLA-B∗13:01 (6.95%). These fre-
quencies were similar to those observed in the Singaporean
Chinese: HLA-B∗40:01 (17.2%), HLA-B∗46:01 (13.2%), HLA-
B∗58:01 (10.4%), HLA-B∗13:01 (8.40%), HLA-B∗15:02 (5.70%)
and Hong Kong Chinese: HLA-B∗46:01 (16.3%), HLA-B∗40:01
(15.2%),HLA-B∗58:01 (7.30%),HLA-B∗15:02 (10.2%) andHLA-
B∗13:01 (7.80%) (Williams et al., 2001; Middleton et al., 2004).
These data differed, however, from the Jehai population in
Malaysia nearest the south of Thailand:HLA-B∗46:01 (2%),HLA-
B∗58:01 (6%), HLA-B∗40:01 (2%), HLA-B∗15:02 (2%), HLA-
B∗13:01 (8%) (Jinam et al., 2010; Kupatawintu et al., 2010;
Romphruk et al., 2010). This may indicate that Thais have a closer
relationship with their Chinese neighbors than with Malaysia.
Previous studies of HLA alleles in the Thai population had larger
subject numbers, but reported no pharmacogenomic data, which
we present in the current study. HLA-B∗15:02 allele is found in
high prevalence among people in South-East Asian countries. The
frequency of theHLA-B allele varies among different populations
suggesting that different alleles may also function in drug hyper-
sensitivity. Currently, there has been an increase of publications
associated withHLA-B alleles and drug hypersensitivity (Sukasem
et al., 2014a).
In our study, 15.92% (n = 157) of Thai subjects carry HLA-
B∗15:02 genotype, which has been associated with severe adverse
drug reaction in response to carbamazepine during epileptic
treatment (Tassaneeyakul et al., 2010; Kulkantrakorn et al., 2012;
Tangamornsuksan et al., 2013) or other aromatic amine anti-
convulsants such as oxcarbazepine, phenytoin, and lamotrigine
(Man et al., 2007; Hung et al., 2010; Koomdee et al., 2014).
Further, the serotype HLA-B75 family, such as HLA-B∗15:08,
HLA-B∗15:11 (0.25%, n = 5), HLA-B∗15:18 (0.15%, n = 3) and
HLA-B∗15:21 (0.15%, n = 3), is associated with carbamazepine-
induced SJS/TEN (Daly and Day, 2009; Lin et al., 2009). In this
study, 168 subjects (17.03%) carrying members of serotype HLA-
B75 family alleles may be susceptible to carbamazepine-induced
SJS/TEN.
The genetic predisposition to nevirapine and abacavir-
induced hypersensitivity reaction (HSR) has been reported for
HLA-B∗35:05 and HLA-B∗57:01 alleles, respectively (Mallal et al.,
2008; Chantarangsu et al., 2009, 2011). The data showed that
4.36% of Thai people carry theHLA-B*35:05 genotype and 3.04%
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Table 3 | Pharmacogenomics markers of HLA-B genotype in a Thai population (n = 986).
HLA-B*15:02 HLA-B*35:05 HLA-B*57:01 HLA-B*58:01
Genotype Subjects % Genotype Subjects % Genotype Subjects % Genotype Subjects %
(n = 157) (n = 43) (n = 30) (n = 161)
B*15:02/46:01 18 1.83 B*35:05/46:01 7 0.71 B*57:01/38:02 3 0.30 B*58:01/40:01 20 2.03
B*15:02/40:01 15 1.52 B*35:05/15:02 5 0.51 B*57:01/44:03 4 0.41 B*58:01/46:01 19 1.93
B*15:02/13:01 12 1.22 B*35:05/40:01 5 0.51 B*57:01/46:01 3 0.30 B*58:01/13:01 13 1.32
B*15:02/44:03 11 1.12 B*35:05/18:01 3 0.30 B*57:01/13:01 2 0.20 B*58:01/15:02 9 0.91
B*15:02/58:01 9 0.91 B*35:05/44:03 3 0.30 B*57:01/18:01 2 0.20 B*58:01/18:02 7 0.71
B*15:02/15:02 8 0.81 B*35:05/13:01 2 0.20 B*57:01/40:01 2 0.20 B*58:01/58:01 9 0.91
B*15:02/18:01 6 0.61 B*35:05/40:06 2 0.20 B*57:01/07:05 1 0.10 B*58:01/52:01 6 0.61
B*15:02/27:04 6 0.61 B*35:05/51:01 2 0.20 B*57:01/13:02 1 0.10 B*58:01/18:01 5 0.51
B*15:02/52:01 6 0.61 B*35:05/15:11 1 0.10 B*57:01/15:01 1 0.10 B*58:01/44:03 5 0.51
B*15:02/15:35 6 0.61 B*35:05/15:17 1 0.10 B*57:01/15:02 1 0.10 B*58:01/46:12 5 0.51
B*15:02/35:05 5 0.51 B*35:05/15:25 1 0.10 B*57:01/15:17 1 0.10 B*58:01/51:01 5 0.51
B*15:02/51:01 5 0.51 B*35:05/18:18 1 0.10 B*57:01/27:06 1 0.10 B*58:01/15:25 3 0.30
B*15:02/18:02 4 0.41 B*35:05/27:06 1 0.10 B*57:01/35:03 1 0.10 B*58:01/35:01 3 0.30
B*15:02/07:05 3 0.30 B*35:05/35:01 1 0.10 B*57:01/35:05 1 0.10 B*58:01/39:09 3 0.30
B*15:02/15:25 3 0.30 B*35:05/35:05 1 0.10 B*57:01/37:01 1 0.10 B*58:01/40:02 3 0.30
B*15:02/38:02 3 0.30 B*35:05/39:09 1 0.10 B*57:01/38:23 1 0.10 B*58:01/53:17 3 0.30
B*15:02/13:02 2 0.20 B*35:05/39:15 1 0.10 B*57:01/40:04 1 0.10 B*58:01/07:05 2 0.20
B*15:01/15:02 2 0.20 B*35:05/40:02 1 0.10 B*57:01/48:01 1 0.10 B*58:01/08:01 2 0.20
B*15:02/15:13 2 0.20 B*35:05/48:01 1 0.10 B*57:01/56:01 1 0.10 B*58:01/15:01 2 0.20
B*15:02/35:01 3 0.30 B*35:05/55:02 1 0.10 B*57:01/58:01 1 0.10 B*58:01/27:04 2 0.20
B*15:02/40:02 3 0.30 B*35:05/57:01 1 0.10 B*58:01/27:06 2 0.20
B*15:02/07:13 1 0.10 B*35:05/58:01 1 0.10 B*58:01/37:01 3 0.30
B*15:02/13:01 1 0.10 B*58:01/38:02 2 0.20
B*15:02/15:06 1 0.10 B*58:01/48:03 2 0.20
B*15:02/15:18 1 0.10 B*58:01/54:01 2 0.20
B*15:02/15:20 1 0.10 B*58:01/55:02 2 0.20
B*15:02/15:88 1 0.10 B*58:01/07:02 1 0.10
B*15:02/18:01 1 0.10 B*58:01/13:02 1 0.10
B*15:02/35:03 1 0.10 B*58:01/15:11 1 0.10
B*15:02/35:58 1 0.10 B*58:01/15:13 1 0.10
B*15:02/40:23 1 0.10 B*58:01/15:20 1 0.10
B*15:02/46:01 1 0.10 B*58:01/15:21 1 0.10
B*15:02/46:12 3 0.30 B*58:01/15:32 1 0.10
B*15:02/51:01 1 0.10 B*58:01/27:03 1 0.10
B*15:02/51:02 1 0.10 B*58:01/35:05 1 0.10
B*15:02/51:04 1 0.10 B*58:01/38:13 1 0.10
B*15:02/51:06 1 0.10 B*58:01/38:20 1 0.10
B*15:02/54:01 1 0.10 B*58:01/39:01 1 0.10
B*15:02/55:02 1 0.10 B*58:01/40:59 1 0.10
B*15:02/55:04 1 0.10 B*58:01/44:02 1 0.10
B*15:02/55:13 1 0.10 B*58:01/46:16 1 0.10
B*15:02/56:01 1 0.10 B*58:01/48:01 1 0.10
B*15:02/56:04 1 0.10 B*58:01/48:21 1 0.10
B*15:02/57:01 1 0.10 B*58:01/56:01 1 0.10
B*58:01/56:04 1 0.10
B*58:01/57:01 1 0.10
B*58:01/07:05 1 0.10
B*58:01/39:09 1 0.10
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FIGURE 1 | “Pharmacogenomics cards” have been successfully implemented in clinical practice in Thailand. The patients are tested for the HLA-B
alleles which are associated with the ADRs related with the use of concerned drugs.
carry the HLA-B∗57:01 genotype (Chantarangsu et al., 2009).
Furthermore, HLA allotypes closely related to abacavir response
are HLA-B∗57:03, HLA-B∗57:02, and HLA-B∗58:01 (Illing et al.,
2012). Consequently, 23.73% of Thai people might be at risk of
drug hypersensitivity from nevirapine or abacavir treatment.
In the present study, we found that 16.33% of Thai people
carry the HLA-B∗58:01 allele, which is associated with allopuri-
nol hypersensitivity in gout treatment (Tassaneeyakul et al., 2009;
Saokaew et al., 2014). Beside drug hypersensitivity, other stud-
ies of HLA-B alleles, such as HLA-B∗46:01, report a significant
increase in severity of cerebral malaria compared with patients
with mild CNS symptoms (Hirayama et al., 1998). Moreover,
HLA-B∗40:01 is associated with lipodystrophy in Thai HIV-1-
positive patients who received antiretroviral therapy containg
stavudine (Wangsomboonsiri et al., 2010).HLA-B∗13:01 has been
suggested as a genetic marker for dermal hypersensitivity asso-
ciated with Trichloroethylene, an industrial solvent (Li et al.,
2007).
Our findings demonstrated the diversity of HLA-B alleles in
the Thai population, and many more HLA associated with ADR.
Other classes of HLA may be observed in upcoming studies. The
subjects enrolled in the study were mostly from central Thailand.
This narrow sample may restrict our calculations of HLA-B allele
distribution in Thai populations. Future studies should consider
this limitation of our survey.
HLA-associated drug hypersensitivity is dependent upon
the different populations studied, and variation in genetic
backgrounds. Recently, HLA-B genotyping has become accessible
in clinical practice, providing appropriate clinical monitoring,
patient counseling and recommendations for treatment.
Interestingly, “pharmacogenetic tests” and “pharmacogenomic
cards” (Figure 1) have been successfully implemented in clinical
practice in Thailand at the Laboratory for Pharmacogenomics,
Somdech Phra Debaratana Medical Center, Ramathibodi
Hospital (Sukasem et al., 2014a). Recently, HLA-B∗15:02 screen-
ing has been preliminarily introduced by the National Health
Security Office (NHSO), Thailand, to screen patients who may
be at risk of carbamazepine-induced SJS/TEN.
In conclusion, our data suggest that HLA-B genotype should
be screened before medication is prescribed to reduce the inci-
dence of drug hypersensitivity. These findings provided useful
information in the study of pharmacogenomics andHLA-B poly-
morphisms in the Thai population. The frequency of the HLA-B
alleles associated with drug hypersensitivity will help in design-
ing alternative treatment regimens or better therapy for affected
individuals. Understanding of the mechanism underlying drug
hypersensitivity reactions requires further investigation.
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